- Our Company
- CMF & Orthopedics
- Biomedical Manufacturing
- News & Events
OPM Receives FDA Clearance for 3D Printed OsteoFab Patient-Specific Facial Device
August 19th, 2014
August 19th, 2014
First and Only FDA Cleared 3D Printed Polymeric Implant to Revolutionize Facial Reconstruction
Oxford Performance Materials, Inc. (OPM), a leading advanced materials and additive manufacturing (3D printing) company, today announced that it has received 510(k) clearance from the FDA for its 3D printed OsteoFab® Patient-Specific Facial Device (OPSFD).
OPM’s facial device is the first and only FDA cleared 3D printed polymeric implant for facial indications, and follows FDA clearance of the first and only 3D printed polymeric implant, OPM’s OsteoFab Patient-Specific Cranial Device, which was granted in February 2013.
"There has been a substantial unmet need in personalized medicine for truly individualized - yet economical - solutions for facial reconstruction, and the FDA’s clearance of OPM’s latest orthopedic implant marks a new era in the standard of care for facial reconstruction,” said Scott DeFelice, Chief Executive Officer and Chairman of Oxford Performance Materials. “Until now, a technology did not exist that could treat the highly complex anatomy of these demanding cases. With the clearance of our 3D printed facial device, we now have the ability to treat these extremely complex cases in a highly effective and economical way, printing patient-specific maxillofacial implants from individualized MRI or CT digital image files from the surgeon. This is a classic example of a paradigm shift in which technology advances to meet both the patient’s needs and the cost realities of the overall healthcare system.”
The OPSFD will be 3D printed by OPM Biomedical, an original equipment manufacturer (OEM) of medical devices utilizing the company’s OsteoFab® process, which combines laser sintering additive manufacturing technology and OPM’s proprietary OXPEKK® powder formulation to print orthopedic and neurological implants. These implants are biocompatible, mechanically similar to bone, radiolucent, and support bone attachment (i.e. osteoconductive).
OPM technology is also designed to reduce the overall “cost of ownership” to the customer by decreasing operating room time, hospital length of stay and procedure complications. In addition, OsteoFab customers do not pay a premium for the individualized 3D printed implant.
“An exciting aspect of our technology is that additional complexity does not increase manufacturing cost, and having both cranial and facial devices cleared now enables us to answer ever more complex cases where upper facial structures can be incorporated with cranial implants as a single device,” added Severine Zygmont, President of OPM Biomedical. “As a result, additive manufacturing has the potential to not only improve patient outcomes, but fundamentally improve the economics of orthopedics on a global scale – for developed and developing countries. These are disruptive changes that will allow the industry to provide the finest levels of healthcare to more people at a lower cost.”
Biomet, Inc., a leading distributor of advanced technologies for the treatment of arthritis, joint and spine related injuries and facial reconstruction, will be the exclusive global distributor of OPM’s OPSFD. Biomet is also the exclusive global distributor of OPM’s OsteoFab Patient-Specific Cranial Device.
About Oxford Performance Materials, Inc.
Oxford Performance Materials (OPM) is a recognized leader in 3D printing and high performance additive manufacturing (HPAM™). OPM has developed a range of advanced materials technology focused on the high performance polymer, poly-ether-ketone-ketone (PEKK). OPM is the first company to successfully apply additive manufacturing solutions using PEKK by utilizing the company’s proprietary OXPEKK® formulation and delivers enterprise level, functional end-use products to the biomedical, aerospace and industrial markets. A pioneer in personalized medicine, OPM became the only company to receive FDA clearance to manufacture 3D printed patient‐specific polymeric implants for its cranial prostheses line in February 2013, and its Biomedical division received a second 510(k) for its patient-specific facial implants in July 2014. OPM's Aerospace & Industrial division has been fulfilling critical development contracts with its OXFAB® technologies for parts in a range of aircraft applications in commercial, defense, and space with its proprietary HPAM™ technology. For more information, please visit: http://www.oxfordpm.com/